• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

    2/12/24 7:11:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    SC 13G/A 1 d662582dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    SANGAMO THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    800677106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen Inc. 33-0112644

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

       6.  

     Shared Voting Power

     

     14,652,466

       7.  

     Sole Dispositive Power

     

       8.  

     Shared Dispositive Power

     

     14,652,466

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     14,652,466 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     8.26%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. 800677106

     

     1.   

     Names of Reporting Persons.

     

     Biogen MA Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     MASSACHUSETTS

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

       6.  

     Shared Voting Power

     

     14,652,466

       7.  

     Sole Dispositive Power

     

       8.  

     Shared Dispositive Power

     

     14,652,466

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     14,652,466 shares

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)1

     

     8.26%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    The percent ownership is calculated based upon an aggregate of 177,346,980 shares of common stock outstanding as of October 30, 2023, as reported in the Sangamo Therapeutics, Inc. Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2023.


    AMENDMENT NO. 1 TO SCHEDULE 13G

    Reference is hereby made to the statement on Schedule 13G relating to the Common Stock of the Issuer filed with the Securities and Exchange Commission by the Reporting Persons on April 17, 2020 (the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

    The following items of the Schedule 13G are hereby amended and restated as follows:

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of cover page.

     

      (b)

    Percent of class:

    See Row 11 of cover page.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See Row 5 of cover page.

     

      (ii)

    Shared power to vote or to direct the vote:

    See Row 6 of cover page.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    Not applicable


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    BIOGEN INC.
    By:   /s/ Michael Dambach
      Name: Michael Dambach
      Title: Treasurer
    BIOGEN MA INC.
    By:   /s/ Michael Dambach
      Michael Dambach
      Treasurer

    Date: February 12, 2024

    Get the next $SGMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

      Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Con

      5/12/25 6:26:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock

      5/12/25 6:23:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web

      5/12/25 4:00:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care